Human insulin-like growth factor

Fahrner, R.L., Lester, P.M., Blank, G.S., and Reifsnyder, D. H., Non-flammable preparative reversed-phase liquid chromatography of recombinant human insulin-like growth factor-I, ]. Chromatogr. A, 830, 127, 1999. 

Efficient secretion and purification of human insulin-like growth factor 1 with a gene fusionvector in staphylococci. Ai/c/eicGrids Rex., 13, 1151-1162. 

A small number of children with growth failure have severe IGF-1 deficiency that is not responsive to exogenous GH. Causes include mutations in the GH receptor and development of neutralizing antibodies to GH. In 2005, the FDA approved mecasermin for treatment of severe IGF-1 deficiency that is not responsive to GH. Mecasermin is a complex of recombinant human IGF-1 (rhIGF-1) and recombinant human insulin-like growth factor-binding protein-3 (rhIGFBP-3). 

Collett-Solberg PF et al The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab 2008 93(1) 10. [PMID 18165284]... 

Fransson JR. Oxidation of human insulin-like growth factor I in formulation studies. 3. Factorial experiments of the effects of ferric ions, EDTA, and visible light on methionine oxidation and covalent aggregation in aqueous solution. J Pharm Sci 1997 86(9) 4046-4050. 

Roy RN, Gerulath AH, Cecutti A, Bhavnani BR. Effect of tamoxifen treatment on the endometrial expression of human insulin-like growth factors and their receptor mRNAs. Mol Cell Endocrinol 2000 165(l-2) 173-8. 

Thrailkill KM, Fowlkes JL, Hyde JF, Litton JC. The effects of co-therapy with recombinant human insulin-like growth factor I and insulin on serum leptin levels in adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2001 2(l) 25-9. 

Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha PM Jr. Cotherapy with recombinant human insulin-like growth factor I and insulin improves gly-cemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. Diabetes Care 1999 22(4) 585-92. 

Murakawa, Y., et al. 1996. Gastrointestinal absorption of recombinant human insulin-like growth factor-I in rats. Proc Int Symp Controlled Release Bioact Mater 23 589. 

C. V. Olsen, D. A. Reifsyuder, E. Conova-Davis, V. T. Ling, and S. E. Builder, Preparative isolation of recombinant human insulin-like growth factor 1 by HPLC, J. Chromatogr., 38 615 (1994). 

Jansson, A., Meldal, M., and Bock, K. (1992) Solid-phase synthesis and characterization of O-dimannosylated heptadecapeptide analogues of human insulin-like growth factor 1 (IGF-1). J. Am. Chem. Soc. Perkin Trans I., 1699-1707. 

Recombinant derived human insulin-like growth factor-1 (rhIGF-1)... 

Lam, X. M.,Duenas,E.T., Daugherty, A. L., Levin,N., and Cleland, J. L. (2000), Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. I. Controlled Release, 67,281-292. 

Hartman ML, Clayton PE, Johnson ML, Celniker A, Perlman AJ, Alberti KG et al. A low dose euglycemic infusion of recombinant human insulin-like growth factor 1 rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. J Clin Invest 1993 91 2453-62. 

Lai EC, Eelice KJ, Eestoff BW, Gawel MJ, Gelinas DE, Kratz R, Murphy MF, Natter HM, Norris FH, Rudnicki SA (1997) Effect of recombinant human insulin like growth factor-1 on progression of ALS. A placebo controlled study. The North America ALS/IGE-1 Study Group. Neurology 49(6) 1621-1630. 

Flirschberg R, Kopple J, Lipsett P,etal. 1999. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney int 55 2423-2432. 

Key CNTF, ciliary neurotrophic factor EPO, erythropoetin HIGF, human insulin-like growth factor HSV-TK, herpesvirus thylimidine kinase IRAP, insulin responsive aminopeptidase. 

New methods use combined HPLC/Mass spectrometry to identify modified amino acids. Purified recombinant human insulin-like growth factor separated into two peaks on reverse phase HPLC (Cl 8 column/acidified water) even though other methods indicated it was completely pure. Plasma desorption mass spectrometry of the individual peptides detected a single methionine sulfoxide molecule that was sufficient to decrease the hydrophobicity of the whole protein significantly. Most of the oxidation occurred when the secreted fusion protein was cleaved with hydroxylamine under not strictly anaerobic conditions, but about 5% occurred during die . coli fermentation. 

Fransson J, Hallen D, and Florin-Robertsson E. Solvent Effects on the Solubility and Physical Stability of Human Insulin Like Growth Factor I. Pharm Res 1997] 14 606-612. 

R9. Rinderknecht, E., and Humbel, R. E., Primary structure of human insulin-like growth factor-II. FEES Lett. 80, 283-286 (1978). 

Fransson, J., and A. Hagman, 1996. Oxidation of human insulin-like growth factor I in formulation studies II. Effects of oxygen, visible light and phosphate on methionine oxidation in aqueous solution and evaluation of possible mechanisms. Pharm. Res. 13 (10) 1476 1481. 

University of Ottawa Human insulin-like growth factor. Human granulocyte-macrophage colony stimulating factor, glycoprotein B from human cytomegalovirus 27, 301-306... 

Panahi M, Cheng X, Callagham M, et al. Expression of human insulin-like growth factor (IGF-I) in plants. 2nd International Molecular Farming Conference London, Ontario, Canada, 1999. 

Panahi M, Alii Z, Cheng X, et al. Recombinant protein expression plasmids optimized for industrial E. coli fermentation and plant systems produce biologically active human insulin-like growth factor-1 in transgenic rice and tobacco plants. Transgenic Res., 2004 13(3) 245-259. 

Giardia lamblia has a unique growth requirement for high concentrations of cysteine which cannot be made de novo (46). The parasite has a cysteine uptake system whieh, in a unique host-parasite interaction, is stimulated by human insulin-like growth factors, especially IGF-II (47). 

Bell, G.I., Gerhard, D.S., Fong, N.M., Sanchez-Pescador, R. and Rail, L.B. (1985) Isolation of the human insulin-like growth factor genes insulin-like growth factor 11 and insu-... 

Besides insulin, other biopharmaceuticals known to exhibit covalent polymerization include recombinant tumor necrosis factor-alpha, which forms nonreducible dimers and oligomers [98], and human insulin-like growth factor I, which is prone to covalent aggregation [99]. 

---